Nektar Therapeutics Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Nektar Therapeutics (NKTR) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $6.29 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-10
- Nektar Therapeutics sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $6.29M, a 32.36% increase year-over-year.
- Nektar Therapeutics sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $7.79M, a 43.09% decline year-over-year.
- Nektar Therapeutics sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $4.45M, a 69.74% decline year-over-year.
- Nektar Therapeutics sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $15.69M, a 21.96% increase year-over-year.
- Nektar Therapeutics sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $32.69M, a 40.95% decline from fiscal 2016.
- Nektar Therapeutics sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $55.35M, a 37.85% increase from fiscal 2015.
- Nektar Therapeutics sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $40.16M, a 59.65% increase from fiscal 2014.
- Nektar Therapeutics sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $25.15M, a 43.91% decline from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $6.29M 10-Q · filed 2018-05-10 | $14.09M derived: sum of 2 quarters · filed 2018-05-10 | $18.53M derived: sum of 3 quarters · filed 2018-05-10 | $34.23M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $7.79M 10-K · filed 2018-03-01 | $12.24M derived: sum of 2 quarters · filed 2018-03-01 | $27.93M derived: sum of 3 quarters · filed 2018-03-01 | $32.69M 10-K · filed 2018-03-01 |
| 2017-09-30 | $4.45M 10-K · filed 2018-03-01 | $20.14M derived: sum of 2 quarters · filed 2018-03-01 | $24.90M 10-Q · filed 2017-11-08 | $38.59M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | $15.69M 10-K · filed 2018-03-01 | $20.45M 10-Q · filed 2017-08-09 | $34.14M derived: sum of 3 quarters · filed 2018-05-10 | $48.84M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | $4.76M 10-Q · filed 2018-05-10 | $18.45M derived: sum of 2 quarters · filed 2018-05-10 | $33.14M derived: sum of 3 quarters · filed 2018-05-10 | $46.01M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $13.69M 10-K · filed 2018-03-01 | $28.39M derived: sum of 2 quarters · filed 2018-03-01 | $41.26M derived: sum of 3 quarters · filed 2018-03-01 | $55.35M 10-K · filed 2018-03-01 |
| 2016-09-30 | $14.70M 10-K · filed 2018-03-01 | $27.57M derived: sum of 2 quarters · filed 2018-03-01 | $41.66M 10-Q · filed 2017-11-08 | $55.64M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $12.87M 10-K · filed 2018-03-01 | $26.97M 10-Q · filed 2017-08-09 | $40.94M derived: sum of 3 quarters · filed 2018-03-01 | $48.18M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $14.10M 10-K · filed 2018-03-01 | $28.07M derived: sum of 2 quarters · filed 2018-03-01 | $35.31M derived: sum of 3 quarters · filed 2018-03-01 | $46.28M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $13.97M 10-K · filed 2017-03-01 | $21.21M derived: sum of 2 quarters · filed 2017-03-01 | $32.18M derived: sum of 3 quarters · filed 2017-03-01 | $40.16M 10-K · filed 2018-03-01 |
| 2015-09-30 | $7.24M 10-K · filed 2017-03-01 | $18.21M derived: sum of 2 quarters · filed 2017-03-01 | $26.18M 10-Q · filed 2016-11-04 | $33.64M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $10.97M 10-K · filed 2017-03-01 | $18.94M 10-Q · filed 2016-08-04 | $26.40M derived: sum of 3 quarters · filed 2017-03-01 | $32.50M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $7.97M 10-K · filed 2017-03-01 | $15.43M derived: sum of 2 quarters · filed 2017-03-01 | $21.53M derived: sum of 3 quarters · filed 2017-03-01 | $27.33M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $7.46M 10-K · filed 2016-02-29 | $13.56M derived: sum of 2 quarters · filed 2016-02-29 | $19.36M derived: sum of 3 quarters · filed 2016-02-29 | $25.15M 10-K · filed 2017-03-01 |
| 2014-09-30 | $6.10M 10-K · filed 2016-02-29 | $11.90M derived: sum of 2 quarters · filed 2016-02-29 | $17.69M derived: sum of 3 quarters · filed 2016-02-29 | $25.73M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $5.80M 10-K · filed 2016-02-29 | $11.60M derived: sum of 2 quarters · filed 2016-02-29 | $19.64M derived: sum of 3 quarters · filed 2016-02-29 | $34.31M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $5.79M 10-K · filed 2016-02-29 | $13.84M derived: sum of 2 quarters · filed 2016-02-29 | $28.51M derived: sum of 3 quarters · filed 2016-02-29 | $38.83M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $8.04M 10-K · filed 2015-02-26 | $22.71M derived: sum of 2 quarters · filed 2015-02-26 | $33.04M derived: sum of 3 quarters · filed 2015-02-26 | $44.85M 10-K · filed 2016-02-29 |
| 2013-09-30 | $14.67M 10-K · filed 2015-02-26 | $25.00M derived: sum of 2 quarters · filed 2015-02-26 | $36.81M 10-Q · filed 2013-11-07 | $47.21M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $10.32M 10-K · filed 2015-02-26 | $22.13M 10-Q · filed 2013-08-09 | $32.54M derived: sum of 3 quarters · filed 2015-02-26 | $40.89M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $11.81M 10-K · filed 2015-02-26 | $22.21M derived: sum of 2 quarters · filed 2015-02-26 | $30.57M derived: sum of 3 quarters · filed 2015-02-26 | $40.26M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $10.40M 10-K · filed 2014-02-27 | $18.76M derived: sum of 2 quarters · filed 2014-02-27 | $28.45M derived: sum of 3 quarters · filed 2014-02-27 | $35.40M 10-K · filed 2015-02-26 |
| 2012-09-30 | $8.36M 10-K · filed 2014-02-27 | $18.05M derived: sum of 2 quarters · filed 2014-02-27 | $24.99M 10-Q · filed 2013-11-07 | $31.07M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $9.69M 10-K · filed 2014-02-27 | $16.64M 10-Q · filed 2013-08-09 | $22.71M derived: sum of 3 quarters · filed 2014-02-27 | $30.39M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $6.95M 10-K · filed 2014-02-27 | $13.02M derived: sum of 2 quarters · filed 2014-02-27 | $20.70M derived: sum of 3 quarters · filed 2014-02-27 | $29.34M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $6.07M 10-K · filed 2013-03-01 | $13.75M derived: sum of 2 quarters · filed 2013-03-01 | $22.39M derived: sum of 3 quarters · filed 2013-03-01 | $24.86M 10-K · filed 2014-02-27 |
| 2011-09-30 | $7.68M 10-K · filed 2013-03-01 | $16.32M derived: sum of 2 quarters · filed 2013-03-01 | $18.79M derived: sum of 3 quarters · filed 2013-03-01 | $29.49M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $8.64M 10-K · filed 2013-03-01 | $11.12M derived: sum of 2 quarters · filed 2013-03-01 | $21.82M derived: sum of 3 quarters · filed 2013-03-01 | $27.30M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $2.47M 10-K · filed 2013-03-01 | $13.17M derived: sum of 2 quarters · filed 2013-03-01 | $18.66M derived: sum of 3 quarters · filed 2013-03-01 | $28.06M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $10.70M 10-K · filed 2012-02-29 | $16.18M derived: sum of 2 quarters · filed 2012-02-29 | $25.58M derived: sum of 3 quarters · filed 2012-02-29 | $27.41M 10-K · filed 2013-03-01 |
| 2010-09-30 | $5.49M 10-K · filed 2012-02-29 | $14.88M derived: sum of 2 quarters · filed 2012-02-29 | $16.71M derived: sum of 3 quarters · filed 2012-02-29 | |
| 2010-06-30 | $9.40M 10-K · filed 2012-02-29 | $11.23M derived: sum of 2 quarters · filed 2012-02-29 | ||
| 2010-03-31 | $1.83M 10-K · filed 2012-02-29 | |||
| 2009-12-31 | $30.12M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |